Regeneron Pharmaceuticals Stock News

With the spotlight firmly on Covid variants, its easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. Its where the largest revolutions will happen. Its the epicenter of the most important [] The post Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK) appeared first on Wall Street PR .

Thrivent Financial for Lutherans boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 42.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 55,199 shares of the biopharmaceutical companys stock after buying an additional 16,546 shares during the quarter. Thrivent Financial for Lutherans []

Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, speaks from the White House on the omicron variant, which was discovered in a patient in California.

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Sandler 33rd Annual Healthcare Conference Call (Transcript)

Exchange Traded Concepts LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,092 shares of the biopharmaceutical companys stock after selling 1,742 shares during the period. Exchange []

Michael Yee, Jefferies biotech analyst and managing director, joins 'Power Lunch' to discuss how company stocks are reacting to rising omicron concerns and which are the best to play with Covid concer

Fifth Third Bancorp grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,460 shares of the biopharmaceutical companys stock after purchasing an additional 3,983 shares during the period. Fifth Third Bancorps []

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been in the spotlight this week, after the company's CEO Leonard Schleifer noted its Covid-19 antibody cocktail may be less effective against the omicro

H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) as a buying opportunity.

H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target . While the company stated the possibility exists that its COVID-19 antibody, REGEN-COV, may lose its potency against the omicron strain, there is limited knowledge about the latest in a series of variants that naturally arise in the environment, analyst Michael King says. Regeneron has already Full story available on Benzinga.com

Regeneron Pharmaceuticals Incs COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Modernas top boss raised similar concerns about the companys vaccine. Global markets tumbled after comments from Modernas chief executive officer rekindled worries that the

Why are stocks down today? It seems that fears over tapering, inflation and the omicron variant are worrying investors on Tuesday.

After Friday’s Omicron variant sell-off, things were looking pretty bleak for investors, but stocks rallied back on Monday. The Nasdaq Composite (COMP:GIDS) led the way, recovering its losses completely and adding a little more for good measure. However, the S&P 500 (SPX) and the Dow Jones Industrial Average ($DJI) were unable to recapture their losses. But the rebound has gone foul as equity index futures are pointing lower Tuesday morning. One warning the market gave yesterday was the fact that the rally was not broad-based. The NYSE only saw 54% of its stocks advancing, while the Nasdaq experienced 57% of its stocks declining. Many smaller stocks also failed to bounce back; the Russell 2000 (RUT) small-cap index dropped another 0.18%. According to Briefing.com, technology stocks were among the strongest, returning 2.6% on the strength of semiconductors. The PHLX Semiconductor Index (NASDAQ: SOX ) rallied 4.1% on the day thanks in part to Lam Research (NASDAQ: LRCX ), which closed the day 6% higher.

H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target.

Regeneron Pharmaceuticals' (REGN) Management on 4th Annual Evercore ISI HealthCONx Conference - Transcript